|
3 | 3 | Code
|
4 | 4 | res
|
5 | 5 | Output
|
6 |
| - Body System or Organ Class |
7 |
| - FMQ (Broad) A: Drug X B: Placebo C: Combination |
8 |
| - Dictionary-Derived Term (N=134) (N=134) (N=132) |
9 |
| - ————————————————————————————————————————————————————————————————————— |
10 |
| - cl B.2 |
11 |
| - FMQ1 20 (14.9%) 17 (12.7%) 22 (16.7%) |
12 |
| - dcd B.2.2.3.1 20 (14.9%) 17 (12.7%) 22 (16.7%) |
13 |
| - FMQ2 22 (16.4%) 25 (18.7%) 21 (15.9%) |
14 |
| - dcd B.2.2.3.1 22 (16.4%) 25 (18.7%) 21 (15.9%) |
15 |
| - FMQ3 18 (13.4%) 24 (17.9%) 23 (17.4%) |
16 |
| - dcd B.2.2.3.1 18 (13.4%) 24 (17.9%) 23 (17.4%) |
17 |
| - cl C.1 |
18 |
| - FMQ1 14 (10.4%) 19 (14.2%) 21 (15.9%) |
19 |
| - dcd C.1.1.1.3 14 (10.4%) 19 (14.2%) 21 (15.9%) |
20 |
| - FMQ2 17 (12.7%) 22 (16.4%) 19 (14.4%) |
21 |
| - dcd C.1.1.1.3 17 (12.7%) 22 (16.4%) 19 (14.4%) |
22 |
| - FMQ3 20 (14.9%) 16 (11.9%) 19 (14.4%) |
23 |
| - dcd C.1.1.1.3 20 (14.9%) 16 (11.9%) 19 (14.4%) |
| 6 | + Body System or Organ Class |
| 7 | + FMQ (Broad) A: Drug X B: Placebo C: Combination |
| 8 | + Dictionary-Derived Term (N=134) (N=134) (N=132) |
| 9 | + —————————————————————————————————————————————————————————————————————— |
| 10 | + cl B.2 |
| 11 | + FMQ1 20 (14.9%) 17 (12.7%) 22 (16.7%) |
| 12 | + dcd B.2.2.3.1 20 (14.9%) 17 (12.7%) 22 (16.7%) |
| 13 | + FMQ2 22 (16.4%) 25 (18.7%) 21 (15.9%) |
| 14 | + dcd B.2.2.3.1 22 (16.4%) 25 (18.7%) 21 (15.9%) |
| 15 | + FMQ3 18 (13.4%) 24 (17.9%) 23 (17.4%) |
| 16 | + dcd B.2.2.3.1 18 (13.4%) 24 (17.9%) 23 (17.4%) |
| 17 | + cl C.1 |
| 18 | + FMQ1 14 (10.4%) 19 (14.2%) 21 (15.9%) |
| 19 | + dcd C.1.1.1.3 14 (10.4%) 19 (14.2%) 21 (15.9%) |
| 20 | + FMQ2 17 (12.7%) 22 (16.4%) 19 (14.4%) |
| 21 | + dcd C.1.1.1.3 17 (12.7%) 22 (16.4%) 19 (14.4%) |
| 22 | + FMQ3 20 (14.9%) 16 (11.9%) 19 (14.4%) |
| 23 | + dcd C.1.1.1.3 20 (14.9%) 16 (11.9%) 19 (14.4%) |
24 | 24 |
|
25 | 25 | # Table 38 generation works with custom values
|
26 | 26 |
|
|
33 | 33 | ————————————————————————————————————————————————————————————————————————
|
34 | 34 | Body System or Organ Class(3)
|
35 | 35 | FMQ (Narrow) A: Drug X B: Placebo C: Combination
|
36 |
| - Dictionary-Derived Term (N=134) (N=134) (N=132) |
| 36 | + Dictionary-Derived Term (N=134) (N=134) (N=132) |
37 | 37 | ————————————————————————————————————————————————————————————————————————
|
38 | 38 | cl A.1
|
39 | 39 | FMQ1 32 (23.9%) 29 (21.6%) 48 (36.4%)
|
|
99 | 99 | Code
|
100 | 100 | res
|
101 | 101 | Output
|
102 |
| - Body System or Organ Class |
103 |
| - FMQ (Broad) A: Drug X B: Placebo C: Combination Risk Difference (%) (95% CI) |
104 |
| - Dictionary-Derived Term (N=134) (N=134) (N=132) (N=268) |
105 |
| - ———————————————————————————————————————————————————————————————————————————————————————————————————— |
106 |
| - cl B.2 |
107 |
| - FMQ1 20 (14.9%) 17 (12.7%) 22 (16.7%) -2.2 (-10.5 - 6.0) |
108 |
| - dcd B.2.2.3.1 20 (14.9%) 17 (12.7%) 22 (16.7%) -2.2 (-10.5 - 6.0) |
109 |
| - FMQ2 22 (16.4%) 25 (18.7%) 21 (15.9%) 2.2 (-6.9 - 11.3) |
110 |
| - dcd B.2.2.3.1 22 (16.4%) 25 (18.7%) 21 (15.9%) 2.2 (-6.9 - 11.3) |
111 |
| - FMQ3 18 (13.4%) 24 (17.9%) 23 (17.4%) 4.5 (-4.2 - 13.2) |
112 |
| - dcd B.2.2.3.1 18 (13.4%) 24 (17.9%) 23 (17.4%) 4.5 (-4.2 - 13.2) |
113 |
| - cl C.1 |
114 |
| - FMQ1 14 (10.4%) 19 (14.2%) 21 (15.9%) 3.7 (-4.1 - 11.6) |
115 |
| - dcd C.1.1.1.3 14 (10.4%) 19 (14.2%) 21 (15.9%) 3.7 (-4.1 - 11.6) |
116 |
| - FMQ2 17 (12.7%) 22 (16.4%) 19 (14.4%) 3.7 (-4.7 - 12.2) |
117 |
| - dcd C.1.1.1.3 17 (12.7%) 22 (16.4%) 19 (14.4%) 3.7 (-4.7 - 12.2) |
118 |
| - FMQ3 20 (14.9%) 16 (11.9%) 19 (14.4%) -3.0 (-11.1 - 5.2) |
119 |
| - dcd C.1.1.1.3 20 (14.9%) 16 (11.9%) 19 (14.4%) -3.0 (-11.1 - 5.2) |
| 102 | + Body System or Organ Class |
| 103 | + FMQ (Broad) A: Drug X B: Placebo C: Combination Risk Difference (%) (95% CI) |
| 104 | + Dictionary-Derived Term (N=134) (N=134) (N=132) (N=268) |
| 105 | + ————————————————————————————————————————————————————————————————————————————————————————————————————— |
| 106 | + cl B.2 |
| 107 | + FMQ1 20 (14.9%) 17 (12.7%) 22 (16.7%) -2.2 (-10.5 - 6.0) |
| 108 | + dcd B.2.2.3.1 20 (14.9%) 17 (12.7%) 22 (16.7%) -2.2 (-10.5 - 6.0) |
| 109 | + FMQ2 22 (16.4%) 25 (18.7%) 21 (15.9%) 2.2 (-6.9 - 11.3) |
| 110 | + dcd B.2.2.3.1 22 (16.4%) 25 (18.7%) 21 (15.9%) 2.2 (-6.9 - 11.3) |
| 111 | + FMQ3 18 (13.4%) 24 (17.9%) 23 (17.4%) 4.5 (-4.2 - 13.2) |
| 112 | + dcd B.2.2.3.1 18 (13.4%) 24 (17.9%) 23 (17.4%) 4.5 (-4.2 - 13.2) |
| 113 | + cl C.1 |
| 114 | + FMQ1 14 (10.4%) 19 (14.2%) 21 (15.9%) 3.7 (-4.1 - 11.6) |
| 115 | + dcd C.1.1.1.3 14 (10.4%) 19 (14.2%) 21 (15.9%) 3.7 (-4.1 - 11.6) |
| 116 | + FMQ2 17 (12.7%) 22 (16.4%) 19 (14.4%) 3.7 (-4.7 - 12.2) |
| 117 | + dcd C.1.1.1.3 17 (12.7%) 22 (16.4%) 19 (14.4%) 3.7 (-4.7 - 12.2) |
| 118 | + FMQ3 20 (14.9%) 16 (11.9%) 19 (14.4%) -3.0 (-11.1 - 5.2) |
| 119 | + dcd C.1.1.1.3 20 (14.9%) 16 (11.9%) 19 (14.4%) -3.0 (-11.1 - 5.2) |
120 | 120 |
|
0 commit comments